| 摘要: |
| 目的 为临床合理使用多黏菌素B(PMB)和多黏菌素E(PME)提供参考依据。方法 收集2004年第1季度至2024年第3季度的美国食品药品监督管理局不良事件报告系统(FAERS)数据,采用报告比值比法(ROR)、英国药品和保健产品管理局(MHRA)综合标准法和贝叶斯可信区间递进神经网络法(BCPNN)进行分析。结果 获取了以PMB、PME为首要怀疑对象的相关神经系统不良事件(AE)分别为24例和91例。大部分报告源自美国(PMB为70.83%,PME为30.77%),医师和药师占主要报告人群。大多数患者年龄较为年轻化(PMB和PME中位年龄分别为32岁和48岁),在44岁以下的患者中,PMB发生AE的构成比高于PME。使用PMB的囊性纤维化及肺病加重患者发生AE的构成比高于PME(35.84%:5.49%)。PMB致神经系统AE的构成比高于PME(ROR[95%CI],1.58[1.13,2.20];PRR[95%CI],1.51[1.13,2.01];χ²,7.46;IC[IC-2SD],0.59[0.09]),且PMB发生外周神经系统的构成比较高,PME发生与神经肌肉有关的构成比较高。此外,PMB和PME在不同的药物剂量下神经AE表现也不同。结论 PMB和PME在不同年龄、适应症和药物剂量下相关神经系统AE的风险特征不同。在临床中应注意采用神经毒性保护剂、提高警惕等对策,保障患者用药安全。 |
| 关键词: 多黏菌素B 多黏菌素E 美国食品药品监督管理局不良事件报告系统 信号挖掘 神经系统 |
| DOI:10.13506/j.cnki.jpr.2025.08.016 |
| 基金项目:白求恩公益基金会“耀动神州-药学科研能力建设基金”项目(No.Z04JKM2023E040);吴阶平医学基金会科研专项资助基金课题(No.320.6750.2023-26-16);山东省药学会共享天晴、“药”有作为学术课题项目(No.Kjyw2024-1) |
|
出版日期:2025-08-25
|
|
| Signal mining and analysis of nervous system adverse events induced by polymyxin B and polymyxin E based on FAERS database |
| GAO Hongzhu1,LIU Yue1,JIN Shanzi1,XU Fengping2,ZOU Dongna3 |
| (1.Department of Pharmacy, The People’s Hospital of Huaiyin, Jinan 250021, China;2.Department of Pharmacy, Shandong First Medical University , Taian 250118,China;3.Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021,China) |
| Abstract: |
| Objective To provide a reference basis for the rational clinical use of polymyxin B (PMB) and polymyxin E (PME). Methods Based on the U. S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data from the first quarter of 2004 to the third quarter of 2024, data mining was conducted using Reporting Odds Ratios (ROR), Medicines and Healthcare products Regulatory Agency (MHRA) , and Bayesian Confidence Propagation Neural Network (BCPNN). Results 24 and 91 patients with nervous system adverse events (AE) related to PMB and PME, respectively. Most reports came from the US (70.83% for PMB, 30.77% for PME), with physicians and pharmacists as the main reporters. Most patients were relatively young (median age 32 for PMB and 48 for PME). In patients under 44 years of age, the constituent ratio of AE associated with PMB is higher than that with PME. PMB had a higher constituent ratio than PME in patients with cystic fibrosis and exacerbated lung disease (35.84% vs. 5.49%). PMB posed a greater constituent ratio of nervous system AE than PME (ROR [95% CI], 1.58 [1.13, 2.20]; PRR [95% CI], 1.51 [1.13, 2.01]; χ², 7.46; IC [IC-2SD], 0.59 [0.09]). PMB was associated with a higher constituent ratio of peripheral nervous system issues, while PME had a higher constituent ratio related to the neuromuscular tube. In addition, PMB and PME show different neurological AE at different drug doses. Conclusion PMB and PME - related nervous system AE risks differ in age, indication, type, and drug dose. In clinical practice, attention should be paid to the use of neurotoxic protective agents, improve vigilance and other countermeasures to ensure the safety of patients. |
| Key words: Polymyxin B Polymyxin E FAERS Signal mining Nervous system |